Mauna Kea Miniprobe Receives FDA Clearance
Microscopy developer Mauna Kea Technologies SA has received its twelfth 510(k) clearance from the U.S. Food and Drug Administration (FDA).
The new FDA clearance covers its confocal miniprobes for use in urological and minimally invasive surgical applications with its NIR (near-infrared) Cellvizio platform. The company said its NIR imaging products are designed to provide a positive impact on procedural outcomes by adding the precision and reliability of real-time cellular characterization to fluorescence-guided procedures.
Mauna Kea is a global medical device company focused on the diagnosis and treatment of cancer through in vivo microscopic visualization.
LATEST NEWS
- Exail Signs LLNL Contract, Partners with Eelume
Apr 26, 2024
- Menlo Moves U.S. HQ: Week in Brief: 4/26/2024
Apr 26, 2024
- Optofluidics Platform Keys Label-, Amplification-Free Rapid Diagnostic Tool
Apr 25, 2024
- DUV Lasers Made with Nonlinear Crystals Enhance Lithography Performance
Apr 25, 2024
- Teledyne e2v, Airy3D Collaborate on 3D Vision Solutions
Apr 24, 2024
- One-Step Hologram Generation Speeds 3D Display Creation
Apr 24, 2024
- Innovation Award Winners for Laser Technology Honored in Aachen
Apr 23, 2024
- Intech 2024: AI Arrives on the Shop Floor
Apr 22, 2024